Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.1 EUR | -3.08% | -3.08% | -1.79% |
Apr. 29 | Theranexus Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Apr. 19 | Theranexus: share price rises following promising trial results | CF |
Business Summary
Theranexus has a unique platform for the identification and characterization of innovative therapy drug candidates in rare neurological disorders and a first drug candidate in clinical development for Batten disease.
Number of employees: 19
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 13-03-18 | |
Founder | - | 13-03-18 | |
Director of Finance/CFO | - | 16-12-31 | |
Marie Sebille
CTO | Chief Tech/Sci/R&D Officer | - | 21-10-18 |
Human Resources Officer | - | 17-12-31 | |
Julien Veys
PRN | Corporate Officer/Principal | - | 15-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jérôme Martinez
BRD | Director/Board Member | 63 | 18-12-12 |
Director/Board Member | 50 | 17-09-25 | |
Founder | - | 13-03-18 | |
Chief Executive Officer | - | 13-03-18 | |
Director/Board Member | 51 | - | |
Eric Doulat
BRD | Director/Board Member | - | 19-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 7,758,724 | 4,220,699 ( 54.40 %) | 0 | 54.40 % |
Company contact information
Theranexus SA
Pépinière Laennec 60, avenue Rockefeller
69008, Lyon
+33 1 88 89 70 31
http://www.theranexus.comSector
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-1.79% | 9.19M | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |
- Stock Market
- Equities
- ALTHX Stock
- Company Theranexus